MeasuredReferenceErlotinib targets EGFR, LOK_STK10, DDR1. Strongest hallmark effect: tumor promoting inflammation.
Top hallmarks
- tumor promoting inflammation2.8k
- evading apoptosis2.3k
- proliferation2.2k
Top pathways disrupted
- apical junction5.2k
- pi3k akt mtor signaling4.9k
- allograft rejection4.8k
Resistance landscape — Erlotinib
MeasuredReference10 known oncogenic variants exist on Erlotinib's top targets — see detail for inhibition impact.